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Abstract
Background:  The Quality of Reporting of Meta-analyses (QUOROM) statement provides
guidance for improving the quality of reporting of systematic reviews and meta-analyses. To make
the process of study selection transparent it recommends "a flow diagram providing information
about the number of RCTs identified, included, and excluded and the reasons for excluding them".
We undertook an empirical study to identify the extent of compliance in the UK Health
Technology Assessment (HTA) programme.
Methods: We searched Medline to retrieve all systematic reviews of therapeutic interventions in
the HTA monograph series published from 2001 to 2005. Two researchers recorded whether each
study contained a meta-analysis of controlled trials, whether a QUOROM flow diagram was
presented and, if so, whether it expressed the relationship between the number of citations and
the number of studies. We used Cohen's kappa to test inter-rater reliability.
Results: 87 systematic reviews were retrieved. There was good and excellent inter-rater reliability
for, respectively, whether a review contained a meta-analysis and whether each diagram contained
a citation-to-study relationship. 49% of systematic reviews used a study selection flow diagram.
When only systematic reviews containing a meta-analysis were analysed, compliance was only 32%.
Only 20 studies (23% of all systematic reviews; 43% of those having a study selection diagram) had
a diagram which expressed the relationship between citations and studies.
Conclusion: Compliance with the recommendations of the QUOROM statement is not universal
in systematic reviews or meta-analyses. Flow diagrams make the conduct of study selection
transparent only if the relationship between citations and studies is clearly expressed. Reviewers
should understand what they are counting: citations, papers, studies and trials are fundamentally
different concepts which should not be confused in a diagram.
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Background
With an estimated seven systematic reviews being pub-
lished every day [1], there is an increasing concern with
the quality of reporting. Recognised standards exist for
reporting meta-analyses of trials and observational studies
[2,3] However there are no standards for systematic
reviews in general (see terminology box for the distinction
between systematic reviews, health technology assess-
ments and meta-analyses). As a result, peer-reviewed pub-
lications frequently demand that standards devised
specifically for reporting meta-analyses should inform the
reporting of systematic reviews more generally. The Qual-
ity of Reporting of Meta-analyses (QUOROM) statement
provides guidance for improving the quality of reporting
of meta-analyses of randomised controlled trials (RCTs).
Its authors state that the QUOROM checklist, "might also
be useful for reporting of systematic reviews" (without sta-
tistical aggregation) and some medical journals (among
them, BMJ and BMC Medicine) now incentivize its use in
systematic reviews, even where there is no meta-analysis,
by making compliance a pre-condition of publication.
Amongst other things, the QUOROM statement attempts
to make the process of study selection transparent, repro-
ducible and systematic: "Authors are asked to provide a
flow diagram providing information about the number of
RCTs identified, included, and excluded and the reasons
for excluding them" (our emphasis) [2].
Terminology Box
Systematic review
     "A review of a clearly formulated question that uses system-
atic and explicit methods to identify, select, and critically
appraise relevant research, and to collect and analyse data from
relevant primary studies. Statistical techniques (meta-analysis)
may or may not be used to summarise the results of the included
studies" [4].
Meta-analysis
     The use of statistical techniques to integrate the results of
primary studies (usually randomised controlled trials) in order
to obtain a more precise estimate of clinical effect. Sometimes
misused as a synonym for systematic reviews, where the review
includes a meta-analysis [4]. A meta-analysis may be published
without a systematic review or health technology assessment,
most frequently when two or more trialists investigating the
same intervention combine their data.
Health Technology Assessment (HTA)
     A process of evidence review and synthesis to support policy
makers. HTAs are sometimes distinguished from systematic
reviews, by the following characteristics: (1) their questions,
methods and the evidence they consider are driven by the inter-
ests of policy-makers rather than those of clinicians or research-
ers; (2) they are inter-disciplinary efforts (most include cost-
effectiveness analyses, unlike systematic reviews which are
mainly confined to analyses of clinical effectiveness); (3) their
results tend to be disseminated outside of the clinical and
research communities [5,6]. Some, but not all HTAs, incorpo-
rate systematic reviews and/or meta-analyses.
This statement assumes that randomised controlled trials
(RCTs) are the only types of primary study to be included
in a systematic review and that it is the study, not the pub-
lication or citation that is the preferred unit of analysis. In
its simplest form, the study selection diagram would
report how many studies  are retrieved, excluded and
included: the diagram would start by counting studies at
the top and conclude by counting studies at the bottom
(Figure 1A). Diagrams recording only studies (as opposed
to citations or publications) might be produced under
two conditions: (a) where a single database is used and
where each record in that database relates to a study per se,
rather than to a citation for a report from that research
study; and, (b) where researchers know the relationship
between bibliographic citations retrieved by the searches
and the number of research studies they represent. For at
least three reasons, neither of these conditions usually
pertains in a systematic review or health technology
assessment.
First, most literature searches use bibliographic databases
in which each record is a citation with a one-to-one rela-
tionship to a publication, not a study. Second, not all publi-
cations relate to research studies; many are editorials, letters
and opinion pieces. Third, there is often not a one-to-one
relationship between studies and publications: most ran-
domised controlled trials will report at multiple follow-up
intervals; many will issue multiple publications at the
same time point. As a result, it is common for reviewers to
have to disentangle the relationship between the numbers
of citations, papers and studies at some point when report-
ing study selection. However, given that the number of
citations retrieved frequently runs into thousands, estab-
lishing the relationship between the total numbers of cita-
tions  retrieved and the studies  they represent would be
laborious, expensive, of questionable value and, in fact, is
rarely undertaken. In summary, the reader cannot assume
a simple one-to-one relationship between citations  and
publications, and there is rarely, if ever, a one-to-one rela-
tionship between either of these and primary research
studies.
As a result, systematic reviewers tend to start the study
selection diagram with the number of bibliographic cita-
tions (not studies) as the unit of analysis, usually (but not
invariably) excluding duplicate citations from different
bibliographic databases. However, most reviewers still
aim to complete the study selection diagram with the
number of studies (not citations) included in the review or
meta-analysis. The authors of this study consider that,BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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compliance with the QUOROM statement, requires that
reviewers make explicit the relationship between the
number of citations and the number of studies at some later
stage in the study selection diagram (as in Figure 1B).
However, this is not widespread practice.
To assess compliance with the study selection diagram
requirement of the QUOROM statement, we undertook
an empirical study of its use in systematic reviews pub-
lished between 2001 and 2005 within the UK NHS Health
Technology Assessment (HTA) programme. The HTA pro-
gramme prioritises and funds research projects, of which
about 20 to 30 per year are systematic reviews of the pub-
lished literature on clinical effectiveness and methodolog-
ical topics. There were two primary objectives: (1) to
record uptake of QUOROM study selection diagrams in,
(a) systematic reviews with meta-analyses; (b) all system-
atic reviews; and, (2) to record how many studies estab-
lish the relationship between citations and studies within
a QUOROM study selection diagram.
Methods
In May 2006, we searched Medline for the HTA pro-
gramme's monographs ("health technology assessment
winchester england.jn") published between 2001 and
2005. Where citations had the phrase "systematic review"
in either the title or the abstract, we retrieved the mono-
graph and confirmed that it was a systematic review of the
published literature on the clinical effectiveness of a ther-
apeutic intervention. Reviews of diagnostic and screening
technologies, qualitative research, methodological
aspects, service delivery or behavioural topics were
excluded.
One researcher (DH) examined the main body and
appendices of all reports, recording whether each study
contained a meta-analysis of controlled trials (excluding
those presented as examples in methodological studies),
whether a QUOROM study selection diagram was pre-
sented and, if so, whether it expressed the relationship
between the number of citations and the number of stud-
ies. Another researcher (AB) extracted (blinded) the same
variables from a 20% sample (n = 19) of all eligible stud-
ies.
Because, strictly speaking, the QUOROM guidelines refer
to the quality of reporting of meta-analyses (rather than all
systematic reviews), we performed separate compliance
analyses, both on all systematic reviews and on the subset
of those containing a meta-analysis of randomised con-
trolled trials. These analyses would thus measure compli-
ance with the implicit and explicit intent of the QUOROM
guidelines. We used Cohen's κ to test inter-rater reliability
for whether or not a review contained a meta-analysis and
Idealised (A) and pragmatic (B) logical study selection diagrams Figure 1
Idealised (A) and pragmatic (B) logical study selection diagrams.BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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whether or not a study selection diagram contained a cita-
tion-to-study relationship [7].
Results
The initial search retrieved 207 citations of which 108 had
the phrase "systematic review" in the title and a further 18
in the abstract (126 in total). Three duplicates were
excluded leaving 123 monographs. Seven monographs
were excluded because they did not contain a systematic
review. Figure 2 shows the study selection process.
Of the remaining 116 studies, all claiming to be a system-
atic review (either in the title or text), we included only 87
which evaluated the clinical effectiveness of therapeutic
interventions. We excluded 12 diagnostic and screening
studies, 11 methods studies, three qualitative studies, two
service delivery studies, and one behavioural study (total
29).
There was good (κ = 0.78) and excellent (κ = 1) inter-rater
reliability for, respectively, whether or not a review con-
tained a meta-analysis and whether or not a study selec-
tion diagram contained a citation-to-study relationship.
Overall, 49% of systematic reviews of clinical effectiveness
illustrated the study selection process with a diagram. The
percentage of compliant reviews had almost doubled
between 2002 and 2004 (from 36% to 68%), but declined
in 2005. Where only systematic reviews containing a
meta-analysis of randomised controlled trials were ana-
lysed, compliance was consistently worse than for all sys-
tematic reviews. Overall, 32% illustrated the study
selection process with a flow diagram. Compliance rose
from 14% to 56% between 2001 and 2004 but declined
in 2005 (Table 1).
Only 20 studies (23% of all systematic reviews; 43% of
those having a study selection diagram), had a diagram
which expressed the relationship between citations and
studies at any point. Of those including a diagram, expres-
sion of the citation to study relationship improved from
29% (2 of 7) in 2001 to 57% (4 of 7) in 2005 (Table 1).
Discussion
Principal findings
Although the QUOROM statement recommends inclu-
sion of a study selection flow diagram, our study shows
that compliance in a sample of recent systematic reviews
was poor. This finding pertained regardless of whether or
not the systematic reviews included a meta-analysis.
While it is true that, on aggregate, compliance has
improved over time; given an unexplained reduction in
prevalence for the most recent year under study it is
unclear whether this trend is continuing.
Furthermore, of those systematic reviews which do illus-
trate study selection using a flow diagram, less than half
enable the reader to follow a transparent process of study
selection from a known number of identified citations to
a known number of studies. It is our contention that,
unless this relationship is made clear, the diagram does
not serve the reader well. Indeed the diagram may actually
confuse readers when there are clear discrepancies in
totals in different boxes.
We recommend that, in those systematic reviews where
reviewers incorporate data sources in which citations do
not have a direct one-to-one relationship with studies,
reviewers make this relationship transparent at some
point in a study selection diagram.
Strengths and weaknesses of the study
This study sampled only a proportion of the recent output
of one publication, the HTA monograph series. The
Study selection for empirical study of QUOROM compliance Figure 2
Study selection for empirical study of QUOROM compli-
ance.BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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results cannot be generalised to other publications. Never-
theless, many researchers working on this series are highly
experienced systematic reviewers and the standard of the
peer review at the HTA programme is considered to be
high. Therefore there is probably sufficient information in
this study to hypothesize that compliance with the
QUOROM statement is poor, six years on.
One criticism of our study could be that might measure
either awareness of, or compliance with reporting stand-
ards on the part of individual researchers or awareness
and enforcement of reporting guidelines on the part of
serial editors. Following the completion of our analysis
the NHS HTA programme confirmed that inclusion of a
study flow diagram been editorial policy since February
2004. In effect then, the first three years of our sample
measure the awareness of reporting standards on the part
of individual researchers, whereas the last two years are
measuring how successful the NHS HTA have been in
enforcement. The mere existence of reporting guidelines
or even a journal's endorsement of them will not necessar-
ily translate into their use by authors, which needs to be
actively enforced [8].
A further criticism of our study might be the use of the
phrase "systematic review" in the title or abstract as an eli-
gibility criterion. If this study were to be repeated in the
journal literature, such a strategy might be considered
unwise: only 50% of reports have this term in the title or
abstract [1]. However, it has been the editorial policy of
the NHS HTA programme to include the words "system-
atic review" in the title of monographs which incorporate
a systematic review over most of our study period (since
2002) so, we believe that the risk of under-retrieval is min-
imal.
Our study demonstrates that the existence of reporting
guidelines does not necessarily lead to improvements in
the conduct of research and that there can be considerable
delay in the adoption of such conventions. Similar delays
have been previously reported in other audits of compli-
ance with publication guidelines [9,10]. Compliance with
such publication standards may be enhanced through the
use of specific requirements at the publication end of the
process such as through inclusion in Instructions to
Authors.
Furthermore such standards are developed following nor-
malisation of previously reviewed data. They may thus be
subject to considerable challenge from the ingenuity and
methodological innovation of researchers when faced
with uncertainties regarding how such guidelines should
be interpreted and implemented.
In this regard, it is important to note that we have not
made the distinction between QUOROM diagram adop-
tion by a publisher and by an individual researcher.
Meaning of the study
Readers of systematic reviews need to be able to under-
stand how the studies included in a systematic review
have been selected. This requires that any supporting dia-
Table 1: Effectiveness reviews illustrating study selection in a flow diagram
All systematic reviews of therapeutic interventions: any flow diagram
N reviews n flow diagrams (%) Citation to study relationship 
(% of all diagrams)
Citation to study relationship: % of all reviews
2001 18 7 (38.9) 2 (28.6) 11.1
2002 22 8 (36.4) 5 (62.5) 22.7
2003 15 8 (53.3) 3 (37.5) 20.0
2004 19 13 (68.4) 6 (46.2) 31.6
2005 13 7 (53.8) 4 (57.1) 30.8
2001–05 87 43 (49.4) 20 (46.5) 23.0
Systematic reviews containing a meta-analysis: any flow diagram
N reviews n flow diagrams (%)
2001 7 1 (14.3)
2002 10 2 (20)
2003 5 1 (20)
2004 9 5 (55.6)
2005 7 3 (42.9)
2001–05 38 12 (31.6)BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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grams are easy to interpret and creates the need for such
diagrams to share a consistent logic across reviews. Our
study shows that, despite the intent of the QUOROM
statement to help researchers make their work transparent
to the reader, at least one component of the guidance, the
study selection flow diagram, is not succeeding in this
regard. It is true that a reader also has access to the textual
narrative by which they can make sense of the conduct of
the review. However this is unlikely to be sufficient and
may carry its own problems.
Recommendations
If the purpose of a flow diagram is to make the conduct of
study selection transparent, reproducible and systematic
(thereby reassuring the reader that attempts were made to
minimize bias), then we believe it is useful for such dia-
grams to be included in any systematic review, regardless
of whether statistical synthesis (meta-analysis) is under-
taken. Making a reference to the relevant published
reporting standards when using a flow diagram encour-
ages dissemination and acceptance by helping the reader
to understand that inclusion of the diagram is an aspect of
good practice. In our sample, very few studies (even
among those with a study selection diagram) actually refer
directly to the QUOROM statement. Without reference to
the QUOROM statement, readers who lack methodologi-
cal experience will not be aware of the reason for, or the
importance of the inclusion of a study selection diagram.
They may also believe that the format and content of such
a diagram is subject to individual interpretation, rather
than representing adherence to a publishing convention.
Every producer, publisher or consumer of systematic
reviews needs to be aware that reporting standards exist.
Transparency in study selection also entails using consist-
ent and transparent terminology within the narrative and
study selection diagram. In particular, it is critical that the
reader can distinguish whether a researcher is counting
citations, publications or studies. The number of citations is
important to researchers when conducting a literature
search; the number of publications is important, after
eliminating duplicates, when undertaking study selection;
but, the number of studies is most important in the final
analysis. For this reason, we recommend that at the earli-
est stage possible within the study selection diagram,
researchers inform the reader how many citations remain
and how many individual studies they represent (account-
ing for studies with multiple publications). We noted con-
siderable variation between technology assessment
reports in terms of the point at which the citation-to-study
relationship is made explicit within the study selection
diagram. Such variation may not in itself prove critical. It
may simply reflect a pragmatic decision on the easiest
point, given review workload, at which the reviewer is
able to switch from citations to studies. Mapping citations
to studies is certainly easier to perform towards the foot of
the diagram, where few studies remain, with a few studies,
than at the head, where there may be thousands of cita-
tions.
In the monographs we reviewed, we noted that some dia-
grams attempted to handle multiple content variables
(Figure 3). These included: (1) study-design-based varia-
bles (example: the diagram distinguishes between system-
atic reviews, RCTs and observational studies); (2) topic-
based variables (example: references to multiple system-
atic reviews of effectiveness in the same diagram); and, (3)
purpose-based variables (example: study selection for a
systematic review of effectiveness and a review of the cost-
effectiveness literature explained in the same diagram). If
a single study selection diagram is used for multiple con-
tent variables, authors need to make sure that the conduct
of study selection is transparent. Where a comparison of
treatment effects involves the assessment of multiple out-
comes, the composition of individual meta-analyses may
involve different numbers of studies. Where it is impracti-
cal, or considered undesirable to present one QUOROM
diagram per meta-analysis, the final box in the diagram
should certainly specify the number of studies in each
meta-analysis, not just that assessing the primary out-
come. Clarity as to the reasons for differential composi-
tion of meta-analyses is important because systematic
reviews as well as clinical trials are subject to outcome
reporting bias [1].
We also noted three different ways of structuring a study
selection flow diagram, characterised as being either
methodological, chronological and logical. The methodo-
logical type prioritises understanding of the review process
and, as a result, may have arrows feeding back between
boxes and/or boxes with no numbers of citations/studies
Diagram handling different review questions and study  designs: from Jones L, Health Technol Assess 2004;8(5) Figure 3
Diagram handling different review questions and study 
designs: from Jones L, Health Technol Assess 2004;8(5).BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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(see Figure 4). As such, they are useful in explaining the
iterative nature of the systematic review process to a new
researcher. The chronological type prioritises explanation
of what the researchers did in strict chronological order:
they may count exclusions made for the same reason in
different boxes, and may thus demonstrate redundancy
with the same number of units given in successive boxes
(Figure 5: "Copies retrieved, n = 87"; "Copies inspected, n
= 87"). The logical type (Figure 1) appears to adhere most
closely to the intent of the QUOROM statement. It is ret-
rospective; it can only be completed when the final com-
position of the meta-analysis is known. The inclusion or
exclusion of units made for the same reason is counted in
the same box regardless of source or chronology. It pro-
vides an audit trail of the conduct of study selection for the
reader, and does not distract the reader with redundant
information about process.
There is considerable variation between study selection
flow diagrams in terms of the point at which papers not
identified through the electronic searches (the results of
handsearching or citation tracking results, grey literature
and papers recommended by expert advisors) are incorpo-
rated. We recommend that these references are included
Methodological diagram: from Cooper BS, Health Technol Assess 2003;7(39) Figure 4
Methodological diagram: from Cooper BS, Health Technol Assess 2003;7(39).BMC Medical Research Methodology 2007, 7:49 http://www.biomedcentral.com/1471-2288/7/49
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in the top box, as it seems to us that this is most consistent
with the logical approach to study selection flow diagram
design.
Attrition of units (whether citations, papers or studies)
through the study selection flow diagram needs to be
transparent. Every stage of the flow diagram should have
an exit box; the numbers in the exit boxes, when aggre-
gated with the "brought forward" box should always rec-
oncile with the total number of studies. There should not
be a failure to account for studies deemed "withdrawals"
(i.e. excluded by application of explicit criteria) or "drop-
outs" (i.e. where a full report of the study in inaccessible
or unavailable) and numbers should decrease as the dia-
gram proceeds down the page. Our study demonstrates
that, for some studies at least, this is not currently the case.
Just as appraisal frameworks for randomised controlled
trials currently require accounting for "withdrawals" and
"dropouts" so too corresponding frameworks for system-
Chronological diagram: from Dalziel K, Health Technol Assess 2003; 7(17) Figure 5
Chronological diagram: from Dalziel K, Health Technol Assess 2003; 7(17).Publish with BioMed Central    and   every 
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atic reviews could require complete accounting for the
progress of studies through the review.
Unanswered questions and future research
A persistent dilemma for those appraising and interpret-
ing any form of published research is the extent to which
it is valid to equate quality of reporting with quality of
conduct for that study. It would be valuable to establish
through empirical research the extent to which a properly
constituted study selection flow diagram, following a log-
ical progression of process and fully accounting for "with-
drawals" and "dropouts", might provide a reliable
indicator of review quality.
Conclusion
Compliance with the recommendations of the QUOROM
statement is not universal in systematic reviews or meta-
analyses. Flow diagrams make the conduct of study selec-
tion transparent only if the relationship between citations
and studies is clearly expressed. Reviewers should under-
stand what they are counting: citations, papers, studies
and trials are fundamentally different concepts which
should not be confused in a diagram.
Standards of reporting, such as those embodied in the
QUOROM statement, seek to improve the transparency of
reporting of methods. In so doing, they carry the implicit
assumption, indeed the aspiration, that this will also
improve the quality of the conduct  of such studies
(although this is yet to be established for other study
designs [9,10]). The results of this study suggest that
reporting guidelines may, in fact, serve an additional pur-
pose, namely to facilitate the identification of variation
and thus aid further refinement of the standards them-
selves. Rather than using existing standards as a methodo-
logical "stick" with which to beat deviant reviewers it is
hoped that studies such as ours, through analysis of vari-
ance, may contribute to the development of standards
that, at once, recognise the diversity of approaches and yet
achieve the consistency and transparency that their origi-
nators intended.
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